REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Oxygen Containing Hetero Ring > The Hetero Ring Is Six-membered > Chalcogen Bonded Directly To Ring Carbon Of The Hetero Ring Chalcogen Bonded Directly To Ring Carbon Of The Hetero RingChalcogen Bonded Directly To Ring Carbon Of The Hetero Ring patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/18/07 - 20070015824 - Serotonin and norepinephrine reuptake inhibitor and uses thereof Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive ... 01/18/07 - 20070015823 - Ambruticin vs compounds where R1, R2, R3 and R4 are as defined herein. Isolated or purified naturally occurring 20,21-dihydro ambruticin compounds. The invention also provides Sorangium cellulosum ambM, ambO, ambP, and ambS mutant strains; a recombinant Sorangium cellulosum strain that produces 24-norambruticin compounds; and a method for treating a fungal infection using a ... 11/09/06 - 20060252824 - Substance with sedative effect A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid, meconic acid, 5-methoxy-gamma-pyrone-2-carboxylic acid, and alike in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 0.05 mg to about 10,000 mg of active ingredient per unit dose of a ... 10/05/06 - 20060223882 - Amorphous simvastatin Amorphous simvastatin is prepared by rapidly removing solvent from a solution comprising simvastatin. The solution can also comprise a pharmaceutically acceptable carrier, to form a dispersion of amorphous simvastatin in the carrier. ... 08/24/06 - 20060189681 - Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain ... 07/13/06 - 20060154981 - Method of reducing intraocular pressure and treating glaucoma The use of 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular hypertension and glaucoma is disclosed. ... 06/29/06 - 20060142380 - 2-phenylpyran-4-one derivatives as selective cox-2 inhibitors The present invention relates to 2-phenylpyran-4-derivatives of general formula (I), processes for their preparation, pharmaceutical compositions containing them, and their medical uses. ... 06/15/06 - 20060128795 - Agents for promoting fattening of animals and method of promoting fattening Agents for promoting fattening of animals which contain as the active ingredient(s) at least one member selected from among acids originating in hexoses, non-toxic salts thereof and intramolecular esterification products thereof; and a method of promoting fattening by using these agents. ... 05/25/06 - 20060111437 - Hyperlipemia therapeutic agent The present invention relates to a hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid or an ester derivative thereof as effective ingredients. According to the present invention, a type IIb and type IV hyperlipemia therapeutic agent having an excellent effect of lowering the cholesterol and triglyceride in blood is provided. ... 05/25/06 - 20060111436 - Compositions and treatments for modulating kinase and/or hmg-coa reductase The present invention provides compositions of matter, kits and methods for their use in the treatment of kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating immuno-compromised and/or cardiovascular conditions in an animal subject by modulating one or more MAP kinase(s) and/or HMG-CoA reductase, as ... 05/18/06 - 20060106094 - Synthetic discodermolide analogs where RA through RE and XA are as defined herein. ... 04/13/06 - 20060079574 - Methods of treating mental diseases, inflammation and pain wherein R is hydrogen, R1 is a halogen, and R2 is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, derivatives of said haloenol lactones, and mixtures thereof. The haloenol lactone, E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one, is most preferred. ... 03/16/06 - 20060058375 - Method of treating dry eye disorders and uveitis The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis. ... 02/02/06 - 20060025474 - Bisphenyl compounds useful as vitamin d3 receptor agonists wherein R1, R2, R3, R4, R5, R6, X, Y, W are defined herein after. These compounds are useful as pharmaceuticals. ... 12/15/05 - 20050277691 - Pravastatin pharmaceutical formulations and methods of their use The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to release little or no pravastatin in the stomach but release a therapeutic amount of pravastatin in the small ... 10/13/05 - 20050228042 - Statin-like compounds The present invention relates to compounds with structures resembling natural statins isolated from Penicillium sp. (Formula I); where R1 represents OH, C6H5COO, R6COO and R6 represents C1-C5 alkyl; R2-4 represents H, C1-C5 alkyl C1-C5 acyl, R5 represents H, CH3; and X represents a compound of (Formula II) or (Formula III). ... 09/15/05 - 20050203174 - Combination therapies using leptomycin b Diseases of cellular proliferation can be treated with a combination of leptomycin B and a chemotherapeutic co-agent, for instance an anti-mitotic agent, a DNA cleaver, an alkylating agent, a DNA crosslinking agent, a DNA intercalator, an HSP90 inhibitor, a topoisomerase I inhibitor, a topoisomerase II inhibitor, an immunosuppressant, an anti-metabolite, ... 09/01/05 - 20050192343 - Nerve growth factor activity potentiating agents wherein X represents hydrogen, CHO, COOH, COOR (wherein R represents an ester residue or an addition salt comprising an alkali metal salt or an organic acid salt group), provided that in case where X is COOH, it is bonded to the carbon atom at the position marked with * so ... 08/11/05 - 20050176812 - Method of treating cancer This invention relates to an alternative regimen for the administration of a discodermolide that is useful for the treatment of cancer. According to the inventive regimen the human patient receives a dose of the discodermolide only once every 3 weeks over the period that the treatment is carried out. ... 08/04/05 - 20050171194 - Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions Compositions comprising a hydroxycarboxylic acid, N-acyl-aldosamine, N-acylamino acid or related compound on topical application are beneficial to plump and pout lips, enhance and firm eyelids, enlarge and augment breasts, elongate and expand penis. Because of antioxidant property, certain hydroxycarboxylic acids, N-acyl-aldosamines, N-acylamino acids and related compounds also are useful for ... 07/28/05 - 20050165091 - Stable pharmaceutical compositions containing pravastatin Stabilized pharmaceutical preparations containing a drug in which is sensitive to a low pH environment, such as pravastatin are disclosed in which pravastatin degradations is prevented with a buffering agent. The basic excipient enhances storage stability. ... 07/21/05 - 20050159480 - Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives The invention relates to a process for the manufacture of a compound of formula: (Formula I); or a salt, especially a pharmaceutically acceptable salt with a base, thereof or a lactone thereof wherein the element (a) represents —CH2—CH2— or —CH═CH— and R represents a cyclic radical. ... 07/21/05 - 20050159479 - Use of pyrone carboxylates for controlling pests wherein R is C2-C6 alkyl, C3-C6 cycloalkyl, (C3-C6 cycloalkyl)C1-C2 alkyl, 3,3,3-trifluoropropyl or 3,3,3-trifluoro-2-methylpropyl to pests or habitats of pests. ... ### FreshPatents.com Support |